Family offices
Geneva family-office owners and portfolio holdings with US-facing positioning needs. Holding-holding brand versus operating brand, US intermediary-facing trust signals, and US co-investment materials.
Family offices in Geneva →
GMA is the global / international marketing agency treating this city as a buyer-evaluation problem inside market-entry marketing. The work is the local-market website, proof order, offer language, AI visibility, paid path, and follow-up a foreign or outbound company needs before serious buyers move.
US marketing for Geneva-headquartered family offices, biotech and medtech owners, engineering-commercial firms, and private-banking-adjacent operators. The Romandie commercial language lands as substance at home and as silence in Cambridge, Boston, and the American intermediary set.
The Geneva business is real. Standing on Quai du Mont-Blanc, in the Romandie biotech corridor, or inside the EPFL spinout cluster has been earned through decades of scientific rigour, regulatory cleanliness, and Swiss-French understatement. The pipeline asset works. The decision is made to put weight into the US market. A US subsidiary opens, a US licensing conversation begins, a US clinical site comes online, or a portfolio company starts its American commercialisation. The first ninety days do not match the model. US meetings happen. US follow-up goes cold.
The instinct is to stay precise, technically grounded, and let the data speak. The instinct is wrong for the American buyer. Geneva commercial culture signals seriousness through specificity, restraint, and Romandie-tier credentials. US biotech and medtech buyers evaluate the same restraint as missing category, missing US peer set, and missing outcome claim. The American evaluator does not interpret Swiss-French precision as authority. They interpret it as untranslated.
American buyers sort fast on three signals: category anchor, outcome claim, and US peer set. Geneva materials tend to omit the first two by design. The work is to translate the Swiss-French identity into US-legible visibility without hollowing out what carries at home.
The American buyer is not asking for louder. They are asking for the category, the outcome, and the peer set. Geneva firms omit those three by habit. House view on Geneva to US entry
The science is not the problem. The structure is not the problem. The American-facing sales material is.
Geneva family-office owners and portfolio holdings with US-facing positioning needs. Holding-holding brand versus operating brand, US intermediary-facing trust signals, and US co-investment materials.
Family offices in Geneva →Geneva lawyers, tax specialists, and trust officers route through the wider Swiss fiduciary channel. No referral fee. Confidential introduction. No commission.
Swiss fiduciary channel →The specific shape of the Romandie biotech and medtech rebuild for Cambridge, Boston, and the wider US commercial set.
Geneva biotech, medtech, US →Six to ten weeks. Single US category, single corridor. GMA rewrites the offer, proof, price story, website, and sales material for the American buyer, then launches the work.
See the Sprint →Three to six months. Multi-channel US rebuild and run. Ads, website, search, sales pages, follow-up, and sales material. The standard shape for Geneva owners committed to US scale.
See the Build →Monthly retainer, twelve-month minimum. Ongoing rebuild-and-run across multiple US website, deck, and sales materials. Typical for Geneva family offices and fiduciary-introduced portfolios with several US-facing brands or holdings.
See the Partnership →No legal services. No Swiss or Geneva-canton company formation, and no US entity formation. No FINMA licensing, L-1, E-2, EB-5, or O-1 visa work. No US tax structuring, FATCA analysis, or double-tax-treaty analysis. No US banking introductions. No fiduciary services. No regulatory licensing. No IP filing. No contract drafting.
These belong with Swiss counsel who specialise in US entry, and with US counsel on the American side. GMA works inside the parameters they set. When a marketing decision carries legal or tax implications, GMA flags it and defers before execution.
Geneva runs on Swiss-French understatement, private-banking heritage, and Romandie-tier credibility. American buyers filter on category anchor, outcome claim, and US peer set before anything else. The Geneva register that signals seriousness on Quai du Mont-Blanc lands as opaque or category-unmoored to a US biotech investor or Cambridge medtech evaluator. GMA does not change at the border. The buyer does. The correction is buyer-language translation, not identity replacement.
Biotech, medtech, engineering-commercial firms, family-office-backed holdings, and private-banking-adjacent operators. GMA also works with Geneva-based fiduciaries introducing client companies to US operators. Fit is checked against the concrete US move, not published sector lists.
No. Swiss company formation, FINMA licensing, US LLC or C-corp formation, L-1, E-2, EB-5, and O-1 visa support, transfer pricing, US tax residency, and US banking introductions are handled by the owner's Swiss counsel and US counsel. GMA builds the US website, deck, proof, and follow-up around the legal and tax structure counsel already chose.
No. GMA does not pay referral fees to Geneva lawyers, tax specialists, trust officers, or family offices who introduce client companies. Introductions carry no referral fee. The fiduciary retains the relationship with the owner. GMA builds the US-facing website, deck, proof, and follow-up around the structure the specialist already manages. Fiduciary introductions route through partnerships@globalmarketing.agency.
With an inquiry through the contact form and an inquiry screening. GMA runs three engagements: Market-Entry Marketing Sprint (6 to 10 weeks), Cross-Border Marketing Build (3 to 6 months), or Global Marketing Partnership (monthly retainer, 12-month minimum). GMA confirms fit and pricing after the inquiry screening. Public prices are not listed.
Playbook for Geneva and Romandie biotech and medtech owners carrying pipeline assets, IP, and licensing data into US commercialisation.
Open the piece →The Swiss-German pair to Geneva. Zurich family offices, fiduciaries, and medtech and biotech owners entering the US.
See Zurich corridor →The wider DACH gate for operators in Germany, Austria, Switzerland, and Liechtenstein.
See the DACH gate →The corridor splits into audience-specific routes. Open the route that matches the situation.
When Swiss regulatory posture is real but not enough for the US category proof check.
Open the file →When Romandie science needs a buyer-proof sales story for the US.
Open the file →When a fiduciary or private-bank introduction needs a clean US website, deck, and sales material.
Open the file →If the market is not responding, the first question is simple: what is the buyer not seeing, trusting, or doing yet?
| Action that should happen | The buyer should request a quote, ask for a call, send an RFQ, move a proposal forward, or hand the work to the right internal person. |
| What may be unclear | If that is not happening, the market may not understand the category, proof, offer, price, channel, service answer, or follow-up. |
| What to inspect | Check the page, sales deck, product proof, offer language, contact path, and follow-up before adding more traffic or more distributors. |
| Next step | If the break is commercial, continue to /engagements/ or /contact/#inquiry. |